-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival for aglatimagene plus valacyclovir after ICI failure

PUBT·10/01/2026 12:06:17
Listen to the news
Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival for aglatimagene plus valacyclovir after ICI failure
  • Candel Therapeutics reported final Phase 2a results in advanced NSCLC patients whose cancers did not respond adequately to checkpoint inhibitors.
  • Results were already presented via a peer-reviewed publication in the Journal for ImmunoTherapy of Cancer.
  • The treatment was associated with longer survival than historical chemotherapy outcomes in this setting, supporting further development.
  • Safety appeared manageable, with mostly mild flu-like side effects; a minority of patients had more serious treatment-related events.
  • Focus now shifts to the ongoing global Phase 3 AURORA study comparing the regimen with docetaxel in metastatic non-squamous NSCLC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010805PRIMZONEFULLFEED9837652) on October 01, 2026, and is solely responsible for the information contained therein.